- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic obstructive pulmonary disease (COPD)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 838KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 42KB)
Tiotropium with olodaterol – July 2020
Tiotropium with Olodaterol: Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses; Spiolto® Respimat®
Last updated
30 October 2020